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Abstract
Background: We examined the association of biomarkers of inflammation and endothelial dysfunction with
diabetes and metabolic syndrome (MetS) in persons from Inner Mongolia.
Methods: A cross-sectional study was conducted among 2,536 people aged 20 years and older from Inner
Mongolia, China. Overnight fasting blood samples were obtained to measure plasma concentrations of high
sensitivity C-reactive protein (hsCRP), soluble inter-cellular adhesion molecule-1 (sICAM-1), sE-selectin, angiotensin II,
high density lipoprotein cholesterol, triglycerides, and blood glucose. Waist circumference and blood pressure were
measured by trained staff. MetS was defined according to the modified ATP III definition for Asians. Elevated level
of the biomarker was defined as values in the upper tertile of the distribution. Participants were categorized into
one of four groups based on the presence or absence of metabolic and glycemic abnormalities: 1) free of
prediabetes, diabetes and MetS (reference group), 2) prediabetes or diabetes only, 3) MetS without prediabetes or
diabetes, and 4) MetS plus prediabetes or diabetes. The multivariable models are adjusted for age, gender,
smoking, drinking, family history of hypertension, and body mass index.
Results: Among study participants, 18.5% had prediabetes, 3.6% had diabetes, and 27.4% of the entire study
population had 3 or more components of the MetS. Elevated hsCRP was associated with an increased odds of
prediabetes or diabetes only, MetS without prediabetes or diabetes, and MetS plus prediabetes or diabetes with
multivariable adjusted odds ratios (95% confidence intervals) of 2.3 (1.7-3.1), 3.0 (2.4-3.8), and 5.8 (4.5-7.5),
respectively. Elevated sICAM-1 was associated with increased odds (95% CI) of prediabetes or diabetes only (2.1,
1.6-2.9) and MetS plus prediabetes or diabetes (4.2, 3.2-5.3) but was not associated with MetS alone. Elevated sE-
selectin was associated with a modestly increased risk of MetS (OR 1.7, 95% CI 1.4-2.2). Elevated levels of
Angiotensin II were not associated with the MetS plus prediabetes or diabetes in this study.
Conclusions: Diabetes and the MetS are common in the Inner Mongolia population. The biomarkers of
inflammation and endothelial dysfunction are associated with increased risk for diabetes and MetS in this
population. These results are consistent with results from other populations.
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The metabolic syndrome (MetS) is common in the Uni-
ted States and has become more prevalent worldwide in
recent years. While much has been written about the
MetS in US and European populations, less is known
about the epidemiology of MetS in non-western coun-
tries [1-3]. In a nationally representative sample of
adults in China, the age-standardized prevalence of
MetS was reported to be higher in women (29.1%) than
men (17.7%), in northern (30.9%) compared to southern
(18.2%) China, and in urban areas (31.0%) compared to
rural (21.6%) areas [4]. It is estimated that 66% of per-
sons with diabetes also have the MetS [5]. In Chinese
adults, the age-standardized prevalence of prediabetes,
diabetes and MetS were reported to be 15.5%, 9.7%, and
23.3%, respectively [4,6].
MetS is characterized by the presence of multiple car-
diovascular risk factors including abdominal obesity,
dyslipidemia, elevated glucos ea n de l e v a t e db l o o dp r e s -
sure [7]. The risk of cardiovascular disease (CVD) mor-
bidity and mortality is elevated among those with MetS
[8-10], and as the number of metabolic abnormalities
increase, the risks of stroke, [11], chronic kidney disease
[12] and CVD [13,14] increase. However, not all of the
components of MetS confer the same amount of risk. In
Western populations, elevated blood glucose may be the
primary force driving the development of MetS and sub-
sequent CVD risk [8]. Diabetes confers a high risk for
CVD mortality that is modified little by the addition of
the other MetS risk factors [15].
Biomarkers of inflammation and endothelial dysfunc-
tion have been associated with diabetes [16-19] and
the MetS [20-22]. They may explain as much as 43%
of the excess risk for CVD mortality among persons
with diabetes [16] and up to 26% of the association
between MetS and coronary artery disease [23]. How-
ever, the associations reported have been inconsistent
in Western and Asian populations [16,20,24-30]. To
o u rk n o w l e d g e ,n op r e v i o u ss t u d yh a se x a m i n e dt h i s
association in persons of Mongolian ethnicity. In the
current study, we examined the association between
biomarkers of inflammation and endothelial dysfunc-
tion with categories of metabolic or glycemic abnorm-
ality in a lean, farming population from Inner
Mongolia, China.
Methods
Subjects
A cross-sectional study was conducted between 2002
and 2003 in Inner Mongolia, an autonomous region in
north China. The methods for selection of study partici-
pants and data collection have been described elsewhere
[31]. Briefly, individuals aged 20 years and older were
recruited from 32 villages in two adjacent townships
located in Kezuohou Banner and Naiman Banner in
Inner Mongolia. The majority of local residents were
Mongolians who had lived there for many generations,
their professions were farmers and herdsmen and they
maintained a traditional diet that was high in fat and
salt. Out of 3,475 eligible people, a total of 2,589 indivi-
duals chose to participate. Those who did not have a
measurement for one or more of the components for
MetS were excluded (n = 53) and a total of 2,536 per-
sons were included in this analysis. Written informed
consent was obtained for all study participants. This
study was approved by the ethics committee at Soochow
University in China and institutional review board at
Tulane University Health Sciences Center in the United
States.
Data Collection
Trained staff interviewed participants in Chinese using a
standard questionnaire to obtain information on demo-
graphic characteristics, medical history, and lifestyle risk
factors such as cigarette smoking and alcohol consump-
tion. Three sitting blood pressure measurements were
taken for each participant using a mercury sphygmo-
manometer according to a standard protocol. The mean
of these three blood pressure measurements was used in
t h ed a t aa n a l y s i s .H e i g h ta n db o d yw e i g h tw e r em e a -
sured by trained staff using a balance beam scale after
subjects removed their shoes and were wearing light
clothing. Body mass index (BMI) was calculated as
weight in kilograms divided by the square of the height
in meters (kg/m
2). Waist circumference was measured
at the level of 1 cm above the umbilicus.
Overnight fasting blood samples were obtained to
measure cholesterol, blood glucose, insulin, high sensi-
tivity C-reactive protein (hsCRP), soluble intercellular
adhesion molecule-1 (sICAM-1), soluble E-selectin (sE-
selectin) and angiotensin II. Plasma and serum samples
were frozen at -80°C until laboratory testing. Concentra-
tions of total cholesterol, high density lipoprotein (HDL)
cholesterol, and triglycerides were assessed enzymatically
on a Beckman Synchrony CX5 Delta Clinical System
(Beckman Coulter, Fullerton, CA, USA) using commer-
cial reagents, and low density lipoprotein (LDL) choles-
terol concentration was calculated by means of the
Friedewald equation for participants who had less than
400 mg/dL triglycerides [32]. Fasting blood was mea-
sured using a modified hexokinase enzymatic method.
Concentration of hsCRP was determined by an immu-
noturbidimetric assay on a Beckman Synchron CX5
Delta Clinical System using commercial reagents. Solu-
ble E-selectin and sICAM-1 was measured by an ELISA
assay (R & D Systems, Minneapolis, MN) which employs
the quantitative sandwich enzyme immunoassay techni-
que. Quantitative determination of immunoreactive
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radioimmunoassay (RIA) after reversed-phase sample
extraction by means of phenylsilylsilica columns follow-
ing the method previously reported by Emanuel et al
and a commercial RIA kit [33]. In total 178 people were
m i s s i n gav a l u ef o r1o ft h e4b i o m a r k e r s .V a l u e sw e r e
imputed by using the median value of the biomarker.
Definitions
Participants who smoked at least 1 cigarette daily for 1
year or more were defined as current smokers. Heavy
alcohol consumption was defined as drinking at least 50
g of alcohol per day for 1 year or more. MetS was
defined according to the modified Adult Treatment
Panel III recommendations for Asian American [34].
I n d i v i d u a l sw e r ec o n s i d e r e dt oh a v eM e t Si ft h e yh a d
three or more of the following risk factors: elevated
waist circumference (≥90 cm in men, ≥80 cm in
women), elevated triglycerides (≥150 mg/dL), reduced
HDL cholesterol (< 40 mg/dL in men, < 50 mg/dL in
women), elevated BP (≥130 mmHg systolic blood pres-
sure or ≥85 mmHg diastolic blood pressure) or elevated
fasting glucose (≥100 mg/dL). Prediabetes and diabetes
cases were defined as individuals with fasting blood glu-
cose measurements of 100-125 mg/dL and ≥126 mg/dL,
respectively.
Statistical Analysis
Participants were categorized into one of four groups
based on the presence or absence of metabolic and gly-
cemic abnormalities: 1) free of prediabetes, diabetes and
MetS (reference group), 2) prediabetes or diabetes only,
3) MetS without prediabetes or diabetes, and 4) MetS
plus prediabetes or diabetes. Descriptive statistics for
demographic variables, components of MetS, and bio-
markers of inflammation and endothelial dysfunction
were calculated separately for the four groups. For con-
tinuous variables, means (standard deviations [SD]) were
used to describe normally distributed variables and med-
ian (interquartile range) were calculated for variables
with skewed distribution; frequencies were used to
describe categorical variables. Differences between the
reference group and other groups were tested using
ANOVA for normally distributed continuous variables;
the Wilcoxon rank-sum test for variables that did not
follow a normal distribution and c
2 for categorical
variables.
For each biomarker, participants were ranked accord-
ing to concentration of the biomarker and then divided
into tertiles. Mean concentrations of individual compo-
nents of the MetS were calculated according to tertile of
biomarker in age and gender-adjusted models and linear
trends were tested. The distribution of participants was
calculated by tertile of biomarker and category of
metabolic or glycemic abnormality. Finally, multivariable
logistic regression was used to calculate the odds ratio
for prediabetes or diabetes, MetS without prediabetes or
diabetes, or MetS plus prediabetes or diabetes according
to tertile of plasma biomarker concentration. Consistent
with other studies, we defined elevated biomarker con-
centration as the upper tertile of the distribution [17].
All p-values were 2-tailed and a significance level of
0.05 was used. All statistical analyses were conducted
using SAS statistical software (version 9.2).
Results
The descriptive characteristics of 2,536 study participants
are presented separately for the four categories of meta-
bolic or glycemic abnormalities (table 1). Study partici-
pants had a mean (SD) age of 46.4 (12.4) years, mean BMI
of 22.2 (3.5) kg/m
2, and 60% were female. In total, 3.6% of
the study participants had diabetes, and 18.5% had predia-
betes. Of those with prediabetes or diabetes, 61% also had
the MetS and 27.4% of the entire study population had 3
or more components of the MetS. Compared to the refer-
ence group, participants with the MetS were more likely
to be female, have elevated BMI, and have a family history
of hypertension. In univariate analysis compared to the
reference group, hsCRP was elevated in all groups,
sICAM-1 was elevated among those with prediabetes or
diabetes, and sE-selectin was elevated in those with MetS.
Table 2 displays the mean levels of individual compo-
nents of the MetS presented by tertile of biomarker in a
model adjusted for age and gender. HsCRP and sICAM-
1 were associated with all components of the MetS (p-
value for linear trend ≤0.01 for all components). Soluble
E-selectin had a linear association with blood glucose,
waist circumference, and triglycerides (p-value < 0.01
for linear trend). Angiotensin II was linearly associated
with blood glucose, triglycerides, and blood pressure (p-
value < 0.01 for linear trend).
Figure 1 shows the proportion of participants by ter-
tile of biomarker and category of metabolic or glycemic
abnormality. More than 40% of participants with predia-
b e t e so rd i a b e t e so n l yo rM e t So n l yh a v eC R Pi nt h e
upper tertile, whereas more than 60% of participants
with MetS plus prediabetes or diabetes have elevated
CRP. For ICAM-1, those in the top tertile comprised
44% of the individuals with prediabetes or diabetes only
and more than 60% of those with MetS plus prediabetes
or diabetes but only 29% of those with MetS only have
elevated ICAM-1. For E-selectin, those in the top tertile
comprised approximately 27% of those with prediabetes
or diabetes only, 44% of those with MetS only, and 36%
of those with the combination of the two conditions.
The proportion of persons with elevated Angiotensin II
was 25% in those with prediabetes or diabetes only, and
35% in the other two categories.
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confidence interval [CI]) for prediabetes or diabetes
only, MetS without prediabetes or diabetes, and MetS
plus prediabetes or diabetes are presented in table 3.
Compared to the reference group, elevated hsCRP was
associated with increased odds for all three groups; the
increased risk was similar for those with prediabetes or
diabetes only (2.27, 1.69-3.06), and MetS only (3.00,
2.35-3.84), but was significantly higher among those
with MetS plus prediabetes or diabetes (5.84, 4.53-7.53).
Elevated sICAM-1 was also associated with increased
odds of prediabetes or diabetes (2.14, 1.60-2.86) and a
4-fold increased risk of MetS plus prediabetes or dia-
betes (4.15, 3.24-5.31). Elevated sE-selectin was asso-
ciated with increased odds of MetS only (1.71, 1.35-
2.17). Elevated Angiotensin II was not significantly asso-
ciated with any of the outcome groups.
When current smoking, heavy drinking, and family
history of hypertension were added to the model, the
results were modestly attenuated. Further addition of
BMI to the model slightly attenuated most results but
did not significantly change the overall results. Finally,
there was no change in the overall results after
excluding individuals with imputed data or excluding
participants with CRP > 10 mg/L.
Discussion
The primary findings of this study are that elevated
levels of CRP and sICAM-1 are associated with
increased odds of prediabetes or diabetes, MetS or both
conditions in combination. Elevated CRP was associated
with nearly 2-fold increased odds of prediabetes or dia-
betes, a 2-fold increased odds of MetS only, and nearly
5-fold increased odds of MetS plus prediabetes or dia-
betes after multivariable adjustment. Elevated sICAM-1
was associated with 2-fold increased odds of having pre-
diabetes or diabetes, and nearly 4-fold increased odds of
having MetS plus prediabetes or diabetes.
In the current study, 3.6% of the study participants
had diabetes which is lower than recent national esti-
mates but 18.5% had prediabetes which is slightly higher
than national estimates [6]. Using the Revised ATP III
definition of the MetS, approximately 27% of the present
study participants had 3 or more metabolic abnormal-
ities, which is similar to national estimates using the
same definition[4].
Table 1 Descriptive characteristics of 2,536 participants according to category of metabolic or glycemic abnormality
No Prediabetes,
Diabetes, or MetS
Prediabetes or
Diabetes only
MetS without
Prediabetes or
Diabetes
MetS plus
Prediabetes or
Diabetes
No. 1621 218 354 343
Age, y 45.3 (12.4) 45.4 (12.8) 48.6 (10.7)* 50.4 (12.2)*
Female, % 57.2 50.1 67.0* 66.2*
Current smoker, % 46.8 42.2 39.3* 39.1*
Alcohol consumption, % 33.4 33.0 33.6 32.4
Body mass index, kg/m
2 21.4 (2.9) 21.0 (3.2) 25.0 (3.3)* 24.3 (3.8)*
Family history of HTN, % 9.9 18.8* 14.4* 22.5*
Components of the Metabolic Syndrome
HDL-C, mg/dL 47.6 (12.3) 48.5 (16.2) 38.3 (8.0)* 39.8 (12.2)*
Triglycerides, mg/dL 86.8 (61.2) 79.6 (40.0) 189.2 (180.7)* 172.7 (177.1)*
Waist circumference, cm 78.1 (7.9) 76.6 (6.8)* 89.2 (8.9)* 87.6 (10.2)*
Systolic BP, mmHg 124.7 (23.2) 126.1 (22.3) 141.5 (23.4)* 142.9 (25.1)*
Diastolic BP, mmHg 81.8 (12.2) 82.1 (11.8) 92.4 (11.3)* 90.5 (12.6)*
Glucose, mg/dL 81.5 (10.8) 112.5 (14.5)* 84.4 (10.2)* 119.7 (34.2)*
Biomarkers of Inflammation and Endothelial Dysfunction
hsCRP, mg/L 5.13 (3.61, 8.25) 7.32 (3.64, 13.84)* 7.89 (5.19, 16.08)* 12.59(5.89, 20.4)*
sICAM-1, ng/mL 315.3 (93.4) 360.3 (85.2) 325.7 (94.7)* 377.6 (89.5)*
sE-selectin, ng/mL 17.9 (14.4, 23.6) 18.3(15.6, 22.3) 20.9 (16.1, 27.6)* 19.9 (16.6, 25.0)*
Angiotensin II, pg/mL 49.4 (39.5, 71.1) 46.7(40.0, 60.0) 50.5 (41.0, 73.8) 49.0(40.0, 86.0)
Abbreviations: BP, blood pressure; HDL-C, high density lipoprotein-cholesterol; hsCRP, high sensitivity C-reactive protein; sICAM-1, soluble intercellular adhesion
molecule-1; sE-selectin, soluble E-selectin. Metabolic syndrome (MetS) was defined according to the revised ATP-III criteria defined as the presence of 3 or more
of the following risk factors: waist circumference ≥90 cm for men and ≥80 cm for women, triglyceride concentration ≥150 mg/dL, blood pressure ≥130/85
mmHg, fasting glucose ≥ 100 mg/dL, or HDL cholesterol level < 40 mg/dL in men or < 50 mg/dL in women. For normally distributed variables, values are
presented as means (SD) or frequencies (%) and as median (interquartile range) for variables that did not follow a normal distribution (hsCRP, sE-selectin, and
angiotensin II). P-values were computed for each category versus the reference category using ANOVA or chi-square for normally distributed variables or
Wilcoxon nonparametric rank test for variables that did not follow a normal distribution, values < 0.05 are denoted with an asterisk (*).
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have reported a significant association between elevated
CRP and prediabetes, diabetes [17,21,26] or MetS
[21,28,30,35]. Our finding that sICAM-1 was associated
with increased odds for prediabetes and diabetes is con-
sistent with the association reported by the Women’s
Health Initiative Observational Study (OR for the high-
est verses lowest quartile of ICAM-1 values: 2.34, 95%
CI 1.75, 3.13) but the odds were higher in the Nurse’s
Health Study (OR for the highest verses lowest quintile
of ICAM-1 values: 3.56, 95% CI 2.28, 5.58), possibly due
to analysis by quintiles rather than tertiles of biomarker
concentration [18,19].
Levels of sE-selectin have been shown to be indepen-
dently associated with diabetes and MetS [18-20].
Ingelsson et al. reported a 26% increased odds of MetS
(OR 1.26, 95% CI 1.06-1.50) for each standard deviation
increase in log E-selectin [20]. Unlike our study, the
Women’s Health Initiative Observational Study found E-
selectin to be a predictor of diabetes; however, the U.S.
women had higher median E-selectin levels, higher
mean BMI and higher mean waist circumference than
the women included in our study [19]. Angiotensin II
has been thought to contribute to altering glucose and
lipid metabolism by inhibiting formation of smaller, less
insulin-resistant adipocytes. Although a positive linear
association was identified between Angiotensin II and
individual components of MetS, elevated angiotensin II
levels were not associated with increased risk of MetS,
prediabetes or diabetes only, or MetS plus prediabetes
or diabetes. To our knowledge, no other studies have
examined this association.
The mechanisms responsible for increased cardiovas-
cular morbidity and mortality in individuals with
Table 2 Mean levels (95% confidence intervals) of individual components of the metabolic syndrome by tertile of
biomarker in a model adjusted for age and gender
Tertiles of
Biomarker
Median Blood Glucose
(mg/dL)
Waist
Circumference
(cm)
Triglycerides
(mg/dL)
HDL Cholesterol
(mg/dL)
Systolic Blood
Pressure (mmHg)
Diastolic Blood
Pressure (mmHg)
hsCRP (mg/L)
1 3.3 84.4 (83.0, 85.9) 78.0 (77.4, 78.7) 81.2 (73.8,
88.7)
47.7 (46.9, 48.6) 127.5 (126.0, 129.0) 83.2 (82.4, 84.0)
2 5.9 86.1 (84.7, 87.5) 80.9 (80.3, 81.5) 99.7 (92.4,
107.0)
45.7 (44.9, 46.6) 128.4 (126.9, 129.9) 84.2 (83.4, 85.0)
3 15.2 98.2 (96.8, 99.6) 83.7 (83.1, 84.3) 162.9 (155.7,
170.2)
42.4 (41.5, 43.2) 133.6 (132.2, 135.2) 87.1 (86.3, 87.9)
P-value for linear trend < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
sICAM-1 (ng/ml)
1 234.3 84.2 (82.8, 85.7) 79.8 (79.2, 80.5) 110.9 (103.3,
118.6)
46.7 (45.8, 47.6) 127.7 (126.2, 129.2) 84.0 (83.1, 84.8)
2 329.0 87.8 (86.4, 89.3) 80.7 (80.6, 81.3) 109.9 (102.3,
117.6)
45.1 (44.3, 46.0) 129.1 (127.5, 130.5) 84.5 (83.7, 85.3)
3 421.4 96.9 (95.4, 98.3) 82.2 (81.5, 82.9) 125.1 (117.5,
132.7)
43.9 (43.0, 44.7) 133.0 (131.5, 134.5) 86.1 (85.3, 86.9)
P-value for linear trend < 0.001 < 0.001 0.01 < 0.001 < 0.001 0.001
sE-selectin (ng/mL)
1 13.6 86.2 (84.8, 87.7) 79.0 (78.4, 79.7) 104.8 (97.1,
112.5)
46.0 (45.1, 46.9) 128.7 (127.2, 130.2) 83.8 (82.9, 84.6)
2 18.3 92.0 (90.5, 93.4) 81.4 (80.8, 82.0) 111.2 (103.6,
118.9)
45.0 (44.2, 45.9) 132.2 (130.7, 133.7) 85.9 (85.1, 86.7)
3 27.9 90.8 (89.4, 92.3) 82.3 (81.7, 82.9) 129.6 (122.1,
137.2)
44.7 (43.8, 45.5) 128.8 (127.3, 130.3) 84.9 (84.1, 85.7)
P-value for linear trend < 0.001 < 0.001 < 0.001 0.04 0.49 0.20
Angiotensin II (pg/mL)
1 36.0 90.8 (89.3, 92.3) 80.8 (80.1, 81.4) 104.1 (96.4,
111.8)
46.1 (45.2, 46.9) 127.1 (125.6, 128.6) 83.4 (82.6, 84.2)
2 48.8 90.4 (89.0, 91.9) 81.0 (80.3, 81.6) 113.2 (105.5,
120.8)
43.8 (43.0, 44.7) 129.7 (128.2, 131.2) 84.8 (84.0, 85.7)
3 89.5 87.9 (86.4, 89.3) 81.1 (80.4, 81.7) 128.3 (120.8,
135.9)
45.8 (44.9, 46.6) 132.9 (131.4, 134.3) 86.3 (85.5, 87.1)
P-value for linear trend 0.003 0.56 < 0.001 0.49 < 0.001 < 0.001
Abbreviations: hsCRP, high sensitivity C-reactive protein; sICAM-1, soluble Intercellular adhesion molecule-1; sE-selectin, soluble E-selectin.
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Figure 1 Proportions of participants with prediabetes or diabetes only, metabolic syndrome without prediabetes or diabetes, and
metabolic syndrome plus prediabetes or diabetes according to the tertile of biomarker concentration.
Table 3 Odds ratios for metabolic or glycemic abnormality associated with elevated biomarkers of inflammation and
endothelial dysfunction
No Prediabetes,
Diabetes, or MetS
Prediabetes or
Diabetes only
MetS without
Prediabetes or
Diabetes
MetS plus
Prediabetes or
Diabetes
hsCRP (mg/L)
Age, gender 1.00 2.27 (1.69, 3.06) 3.00 (2.35, 3.84) 5.84 (4.53, 7.53)
Multivariable 1.00 2.22 (1.65, 3.00) 2.97 (2.33, 3.80) 5.70 (4.41, 7.33)
Multivariable + BMI 1.00 2.29 (1.69, 3.10) 2.38 (1.82, 3.11) 4.82 (3.69, 6.31)
sICAM-1 (ng/ml)
Age, gender 1.00 2.14 (1.60, 2.86) 1.13 (0.88, 1.46) 4.15 (3.24, 5.31)
Multivariable 1.00 2.06 (1.54, 2.76) 1.10 (0.85, 1.43) 3.98 (3.10, 5.12)
Multivariable + BMI 1.00 2.11 (1.58, 2.83) 0.91 (0.69, 1.21) 3.43 (2.64, 4.47)
sE-selectin (ng/mL)
Age, gender 1.00 0.82 (0.60, 1.12) 1.71 (1.35, 2.17) 1.27 (0.99, 1.62)
Multivariable 1.00 0.82 (0.60, 1.13) 1.71 (1.35, 2.17) 1.28 (1.00, 1.64)
Multivariable + BMI 1.00 0.85 (0.62, 1.17) 1.38 (1.06, 1.79) 1.06 (0.81, 1.38)
Angiotensin II (pg/mL)
Age, gender 1.00 0.63 (0.45, 0.87) 1.09 (0.85, 1.39) 1.05 (0.82, 1.35)
Multivariable 1.00 0.63 (0.45, 0.87) 1.06 (0.83, 1.36) 1.00 (0.78, 1.29)
Multivariable + BMI 1.00 0.62 (0.45, 0.86) 1.12 (0.86, 1.46) 1.05 (0.80, 1.37)
Abbreviations: MetS, Metabolic Syndrome; hsCRP, high sensitivity C-reactive protein; sICAM-1, soluble Intercellular adhesion molecule-1; sE-selectin, soluble E-
selectin; BG, blood glucose. The multivariable models are adjusted for age, gender, smoking, drinking and family history of hypertension.
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risk factors and may be partially explained by inflamma-
tion and endothelial dysfunction. Visceral adiposity is
associated with increased production of proinflamma-
tory cytokines and hepatic CRP. ICAM-1 is also asso-
ciated with visceral adiposity and may be upregulated by
the increased production of proinflammatory cytokines
[36]. Inflammation may promote development of dia-
betes by triggering beta cell dysfunction, apoptosis and
impaired insulin signaling or development of hyperten-
sion by influencing platelet adhesion and aggregation,
production of oxidants and induction of renal vasocon-
striction [37].
The median level of CRP in our study participants was
higher than reported in other studies with Asian popula-
tions [26,28,30,35] and may be due to analytic or pre-
analytic sources of variability such as a lack of standar-
dized reference material for CRP measurement, inclu-
sion of participants with CRP > 10 mg/L, diet high in
fats and salts or subclinical or untreated disease.
This study has several strengths including homoge-
neity of lifestyle, dietary habits and ethnic background
of study participants. Study personnel were well
trained and data was collected with rigid quality con-
trol. Due to the cross sectional nature of this study, it
is not possible to establish temporality or determine if
elevated biomarkers lead to development of the predia-
betes, diabetes or MetS or if development of the indi-
vidual components of the MetS lead to inflammation
and endothelial dysfunction. Additional limitation
includes the fact that prediabetes and diabetes were
defined based on the fasting glucose along, which will
underestimate the prevalence [6].
Conclusions
In conclusion, the results from our study, indicated a
strong association between elevated biomarkers of
inflammation and endothelial dysfunction with increased
odds of prediabetes, diabetes and the MetS among
adults in Inner Mongolia, China. Strategies to reduce
inflammation may be important therapeutic targets for
people at risk of developing diabetes or MetS.
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